Introduction
============

Chagas disease, originally described by the Brazilian researcher, Carlos Justiniano Ribeiro Chagas, in 1909 is one of the most widely distributed infectious diseases on the American continent, especially in Latin America, with approximately 25 million people living in risk areas. An estimated 10 million individuals are infected worldwide mostly in Latin America^([@R01])^. The gradual control of natural transmission, mainly due to eradication of the vector in various countries where the disease is endemic, demonstrates the presence of secondary mechanisms of Chagas disease transmission, especially transfusional transmission^([@R02]-[@R05])^.

Scientific-technical progress in the fight against Chagas disease intensified in the 1980s. Thus, the intensification and standardization of sanitary surveillance measures by public andprivate blood centers in endemic countries - that began in the late 1960s in some Latin Americancountries - markedly contributed to a reduction in the frequency of non-negative serology for*Trypanosoma cruzi*among blood donors. While in the 1980s the predominance of seropositivedonors in Latin America was 6%, this index dropped to 1.28 % by 2006^([@R02])^. Concomitantly,transfusional transmission cases of Chagas disease have occurred in North America, Europe,Japan and Australia^([@R01],[@R04])^. Thus Chagas disease, which until recently had been seen as a seriousLatin-American public health problem, has become a global public health threat. Especially withrespect to the quality control of serological screening for Chagas disease among blood donors,the occurrence of false-positive results may lead to unnecessary disposal of blood units andconsequently compromise the blood supply at blood centers. In addition, there are psychologicaland social consequences for the ineligible donor who believes that he has a stigmatized chronicdisease. On the other hand, the occurrence of false-negative results may lead to transfusionaltransmission of Chagas disease. The greatest challenge currently encountered by blood banksis the frequent occurrence of inconclusive reactions, most of which are observed among nonchagasic donors; this indicates failure in the specificity of screening tests^([@R06]-[@R08])^.

In view of the lack of consensus in the international literature regarding the diagnostic test that correctly classifies a subject as seropositive or seronegative for Chagas disease (100% sensitivity and specificity), numerous researchers have proposed to improve the existing variations of the enzyme-linked immunosorbent assay (ELISA) - one technique recommended by ANVISA, the Brazilian National Heath Surveillance Agency for screening donors - for example, by replacing natural *T. cruzi*antigens with recombinant antigen mixtures^([@R09]-[@R12])^.

Several investigators have also proposed the inclusion of aclinical-epidemiological chart to assist in the investigation anddefinition of the true serological profile of ineligible donors,especially those presenting inconclusive reactions^([@R07],[@R13]-[@R15])^. This chart would include questions regarding the place and type of residence, afamily history of Chagas disease, a history of contact with the vector,and a history of blood transfusions and surgery. This procedure hasbeen shown to be effective in the differentiation between donors with or without*T. cruzi* infection when used simultaneously withserological and/or molecular biology tests^([@R07],[@R14])^, and will certainly bean important tool for the selection and exclusion of blood donorsat blood centers in countries or geographic regions where Chagasdisease is not endemic^([@R15])^.

Thus, the goal of this work is to evaluate the efficacy of the blood culture test and five commercial tests (ELISA, IIF, HAI, c-ELISA, rec-ELISA) used in screening blood donors for Chagas disease, as well as to investigate the prevalence of *T. cruzi*infection among donors with inconclusive serology screening in respect to some epidemiological variables.

Methods
=======

The target population of this study was stratified from a total of 95,990 donations based on a retrospective study ofthe database of the Uberaba Regional Blood Center (URBC)conducted between January 2000 and December 2005. From 269non-negative donors for Chagas disease (0.28%), 60 participantswere randomly selected: Stratum II: 30 donors repeatedly positiveusing two screening tests (ELISA and IIF) and Stratum III: 30donors with inconclusive serology in the ELISA screening testor with discordant results in two tests. Additionally 30 donorswith more than five negative donations at URBC over a six-yearperiod (Stratum I) were included. This number was fixed due to thedifficulty in contacting ineligible donors, especially those ineligiblebefore 2003, which led to sample loss. The main reasons for this losswere changes of address and telephone number (30.4%), residingmore than 120 km from Uberaba (26.4%), refusal to participatein the study (7%) and death (2%). All participants answered thefollowing socio-epidemiological questionnaire: type of donor (first time, repeat), age (\< 30: \> 30 years), gender (male: female), livingin an endemic region (yes: no), contact with the vector transmittingChagas disease (yes: no) and a family history of Chagas disease(yes: no). A 30-mL sample of blood was drawn for each participantto perform five serological tests and a parasitological test.

In addition to the commercial ELISA test (ELISA cruzi^(r)^ bioMérieux Diagnostica SA, Rio de Janeiro, Brazil), five other immunodiagnostic screening tests were performed in theninety donors invited to participate in the study including: thecommercial ELISA test (ELISA Chagatest^(r)^ Wiener Lab, Rosario, Argentina); indirect immunofluorescence test (IIF - Imunocruzi^(r)^, bioMerieux Diagnostics SA, Rio de Janeiro, Brazil); indirecthemagglutination (IHA - Chagatest^(r)^, Wiener Lab, Rosario,Argentina); conventional ELISA (c-ELISA) which uses antigensderived from *T.* cruzi lysate and recombinant ELISA (rec-ELISA) using the recombinant antigens cytoplasmic repetitive antigen (CRA) and flagellar repetitive antigen (FRA) (EIE-Recombinant-Chagas Bio-Manguinhos^(r)^, Bio-Manguinhos Laboratory, Oswaldo Cruz Foundation / FIOCRUZ, Brazilian Ministry of Health) and the blood culture test (HEMO), the only test that is known to be 100% specific as it demonstrates the presence of the parasite.

Statistical Analysis
--------------------

Due to the absence of a gold standard for the diagnosis ofChagas disease, a Bayesian latent class statistical model was considered in this particular case of six diagnostic tests, six covariatesin the logit model^([@R16],[@R17])^ considering the assumption proposed by Hui & Walter^([@R18])^, with different prevalence rates for chagasic infectionbut with a similar test performance among strata (SI: negative,SII: positive and SIII: inconclusive serology in the screening). Thenumerical Bayesian algorithm (Metropolis-Hastings algorithm) andthe convergence evaluation were implemented in package R, whichis freely available from [www.r-project.org](http://www.r-project.org). The codes designed forthe present study can be requested by e-mail from the authors.

Ethical Aspects
---------------

The study was approved by the Ethics Committee of Universidade Federal do Triângulo Mineiro (UFTM - protocol \# 464) and all participants signed consent forms.

Results
=======

[Table 1](#T1){ref-type="table"} shows the results of the six tests under investigation for each of the three strata according to the result of serologicalscreening at the time of donation. It was observed that 90% of donors with negative and 80% with inconclusive screening results were negative in all six tests investigated. Among the 30 donors with positive screening results, 96.6% had five or six positive results in the tests under investigation.

On analyzing the performance of tests without considering the covariates and the blood culture test, the general sensitivity between tests is very similar and higher than 97.63%. Two tests (IHA and IIF) were more specific with rates of 98.48% and 98.52%, respectively ([Table 2](#T2){ref-type="table"}).

###### 

Results of the tests under investigation according to the result at the time of screening test

                      **Screening results**                                           
  ---- ---- ---- ---- ----------------------- ---- ---------- ----------- ----------- ----------
  \-   \-   \-   \-   \-                      \-   27(90.0)   0 (0)       24 (80.0)   
  \-   \-   \-   \-   \+                      \-   2 (6.7)    0 (0)       5 (16.7)    
  \+   \-   \-   \-   \-                      \-   1 (3.3)    0 (0)       1 (3.3)     
  \+   \+   \-   \-   \+                      \-   0 (0)      1 (3.3)     0 (0)       
  \+   \+   \+   \-   \+                      \+   0 (0)      17(56.7)    0 (0)       
  \+   \+   \+   \+   \+                      \+   0 (0)      12 (40.0)   0 (0)       
                                                   Total      30 (100)    30 (100)    30 (100)

ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofuorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: conventional ELISA using the Bio-Manguinhos kit; rec-ELISA (recombinant ELISA using the Bio-Manguinhos-FIOCRUZ kit and CRA and FRA antigens)

###### 

Sensitivity (%) and specifcity (%) of the six tests under investigation according to each level of the six covariates involved

  **Sensitivity (%)**                                                                                                                                   
  ------------------------- ----------- ---------- --------- ---------- ------------- --------------- -------- ---------- -------- ---------- -------- ------
      General               97.76       0.88       97.64     0.93       97.70         0.85            58.07    0.80       97.63    0.93       97.76    0.90
      First time donor      98.23       0.70       98.19     0.73       98.23         0.66            57.75    0.80       98.14    0.73       98.27    0.70
      Repeat donor          97.17       1.11       96.94     1.20       97.01         1.11            58.38    0.79       96.98    1.17       97.11    1.15
      Age \< 30 years       94.53       2.13       94.17     2.23       94.29         2.08            55.71    0.84       94.17    2.21       94.41    2.21
      Age \> 30 years       99.10       0.37       99.06     0.39       99.09         0.36            60.38    0.82       99.05    0.39       99.12    0.37
      Male                  95.21       1.86       94.84     2.02       94.98         1.84            58.57    0.79       94.96    1.93       95.15    1.89
      Female                98.96       0.43       98.94     0.44       98.96         0.40            59.57    0.80       98.90    0.45       98.98    0.43
  **Endemic region**                                                                                                                                    
      No                    95.67       1.70       95.38     1.80       95.50         1.66            56.91    0.81       95.43    1.77       95.61    1.73
      Yes                   98.85       0.47       98.81     0.49       98.83         0.45            59.22    0.80       98.78    0.49       98.87    0.47
  **Contact with vector**                                                                                                                               
      No                    96.54       1.35       96.31     1.44       96.39         1.33            56.33    0.82       96.29    1.44       96.50    1.39
      Yes                   98.55       0.58       98.50     0.60       98.54         0.55            59.78    0.81       98.49    0.60       98.58    0.58
  **Family history**                                                                                                                                    
      No                    94.44       2.16       94.03     2.31       94.20         2.13            56.01    0.83       94.21    2.23       94.30    2.26
      Yes                   99.11       0.37       99.09     0.38       99.10         0.35            60.09    0.81       99.05    0.39       99.14    0.36
                                                                                                                                                       
  **Specificity (%)**                                                                                                                                   
                                                                                                                                                       
  **Covariate**             **ELISA**   **IIF**    **IHA**   **HEMO**   **c-ELISA**   **rec-ELISA**                                                    
  **Mean**                  **SD**      **Mean**   **SD**    **Mean**   **SD**        **Mean**        **SD**   **Mean**   **SD**   **Mean**   **SD**   
                                                                                                                                                       
      General               97.25       0.99       98.52     0.66       98.48         0.67            100      0          97.71    0.89       97.77    0.83
      First time donor      97.56       0.88       97.93     0.91       97.74         0.99            100      0          96.22    1.46       96.38    1.33
      Repeat donor          96.90       1.11       98.95     0.47       98.98         0.45            100      0          98.62    0.55       98.63    0.51
      Age \< 30 years       92.18       2.84       95.51     2.00       95.48         2.02            100      0          95.53    1.73       95.63    1.61
      Age \> 30 years       99.06       0.36       99.52     0.22       99.50         0.23            100      0          98.83    0.47       98.87    0.43
      Male                  93.83       2.20       95.98     1.77       96.07         1.74            100      0          96.05    1.52       96.13    1.43
      Female                98.79       0.46       99.46     0.25       99.42         0.27            100      0          98.68    0.53       98.72    0.49
  **Endemic region**                                                                                                                                    
      No                    94.28       2.05       96.72     1.45       96.69         1.47            100      0          95.88    1.57       95.93    1.50
      Yes                   98.70       0.48       99.34     0.30       99.31         0.31            100      0          98.73    0.51       98.78    0.46
  **Contact with vector**                                                                                                                               
      No                    96.02       1.42       98.96     0.47       98.97         0.46            100      0          98.20    0.71       98.24    0.66
      Yes                   98.11       0.69       97.90     0.93       97.76         0.98            100      0          97.09    1.13       97.17    1.04
  **Family history**                                                                                                                                    
      No                    91.66       2.98       95.11     2.18       95.10         2.13            100      0          93.63    2.43       93.70    2.37
      Yes                   99.12       0.35       99.56     0.21       99.54         0.22            100      0          99.19    0.34       99.22    0.30

SD: Standard Deviation; ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofuorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: conventional ELISA using the Bio-Manguinhos kit; rec-ELISA (recombinant ELISA using the Bio-Manguinhos-FIOCRUZ kit and CRA and FRA antigens)

There was an increase in these rates when the covariates were taken into account, for example, all tests had sensitivities equal to orgreater than 99.05% for donors older than 30 years and with a historyof Chagas disease in the family; the ELISA, IIF and IHA tests hadspecificity rates above 99.05% for these same categories ([Table 2](#T2){ref-type="table"}).

Despite the very similar nominal values, the sensitivity rates of all serological tests (ELISA, IIF, IHA, c-ELISA and rec-ELISA) were higher in over 30-year-old donors, females, who came from an endemic region, who had had contact with the vector and had a family history of Chagas disease. The IIF, IHA, c-ELISA and rec-ELISA tests were found to be more specific in repeat donors, over 30-year-old donors, females, who came from an endemic region, who had not had contact with the vector and had a family history of Chagas disease. In contrast, the ELISA test was more specific in first time donors who had had contact with the vector transmitting the disease ([Table 2](#T2){ref-type="table"}).

With respect to the prevalence of Chagas disease, an overallestimate of 13.30% was observed among donors with inconclusiveserology in the screening test at the time of blood donation but thisrate varied considerably depending on the covariates ([Table 3](#T3){ref-type="table"}).

###### 

Prevalence rates (%) of Chagas disease for donors with inconclusive serology (Stratum III), according to the six covariates

                            **Prevalence**           
  ------------------------- ---------------- ------- ------
      General                                13.30   0.22
      First time donor                       15.22   0.25
      Repeat donor                           11.59   0.20
      Age \< 30 years                        9.23    0.16
      Age \> 30 years                        18.79   0.30
      Male                                   9.90    0.17
      Female                                 17.64   0.28
  **Endemic region**                                  
      No                                     13.73   0.00
      Yes                                    15.71   0.00
  **Contact with vector**                             
      No                                     11.98   0.00
      Yes                                    19.38   0.00
  **Family history**                                  
      No                                     9.55    0.00
      Yes                                    18.19   0.00

SD: Standard Deviation

When we consider testing in series which is suitable for situations that require greater specificity, where the diagnostic result is positive if all tests have positive results, we find a specificity of over 99.93% for all pairs of tests (not including the blood culture test) and 100% when we consider the ELISA, IIF, IHA tests together. While, the parallel scheme, indicated for urgent cases or for quality control as in blood banks, in which the set of tests is considered to be positive when at least one of the tests is positive, we found a sensitivity of over 99.96% for all pairs of tests (not including the blood culture test) and 100% when we consider ELISA, IIF, IHA tests together ([Table 4](#T4){ref-type="table"}).

###### 

Sensitivity (%) and specifcity (%) of the five tests under investigation (not including the blood culture test) with parallel and serial testing schemes

                        **Parallel**   **Serial**                                         
  --------------------- -------------- ------------ ------- ------ ------- ------ ------- ------
  ELISA + IIF           99.96          0.06         95.23   2.33   95.98   2.44   99.94   0.06
  ELISA + IHA           99.96          0.07         95.13   2.38   95.94   2.50   99.94   0.07
  ELISA + c-ELISA       99.96          0.06         94.61   2.48   95.97   2.41   99.93   0.07
  ELISA + rec-ELISA     99.96          0.05         94.70   2.46   96.10   2.30   99.93   0.06
  IIF + IHA             99.96          0.06         95.72   1.92   95.87   2.46   99.95   0.05
  IIF + c-ELISA         99.96          0.07         95.20   2.06   95.91   2.40   99.94   0.05
  IIF + rec-ELISA       99.96          0.05         95.29   2.05   96.04   2.32   99.94   0.05
  IHA + c-ELISA         99.96          0.05         95.10   2.10   95.86   2.39   99.94   0.06
  IHA + rec-ELISA       99.96          0.06         95.20   2.12   96.00   2.35   99.94   0.06
  c-ELISA + rec-ELISA   99.96          0.05         94.68   2.25   96.03   2.27   99.93   0.07
  ELISA + IIF + IHA     100            0.00         94.41   2.01   93.23   2.00   100     0.00

SD: Standard Deviation; ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofuorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: conventional ELISA using the Bio-Manguinhos kit; rec-ELISA (recombinant ELISA using the Bio-Manguinhos-FIOCRUZ kit and CRA and FRA antigens)

The predictive values (positive and negative) of all combinationsof pairs of the five serological tests (ELISA, IIF, HAI, c-ELISA, rec-ELISA) confirm the presence of *T. cruzi* infection with a probability of100% in the stratum of donors with positive serology screening whenat least one of two tests has a positive result. In the stratum of donorswith negative serology screening results, it is possible to affirm theabsence of Chagas disease with a probability of 100% when at leastone of two tests shows negative results. However, in the stratum ofdonors with inconclusive serology it is possible to confirm the absenceof Chagas disease with a probability of 100% when the two tests havenegative results depending on the epidemiological variables ([Table 5](#T5){ref-type="table"}).

###### 

Negative predictive value (%) for three pairs of tests according to the parallel and serial testing schemes as well as epidemiological variables for donors with inconclusive serology screening

                            **Parallel**   **Serial**                                                                       
  ------------------------- -------------- ------------ ------- ------ ------- ------ ------- ------ ------- ------ ------- ------
      General               99.98          0.03         99.98   0.02   99.98   0.02   98.36   1.11   98.42   1.01   98.38   1.06
      First time donor      99.99          0.01         99.99   0.01   99.99   0.02   99.41   0.55   99.42   0.56   99.40   0.58
      Repeat donor          99.99          0.06         99.99   0.03   100     0.03   98.86   1.99   98.93   1.75   98.95   1.73
      Age \< 30 years       99.63          0.58         99.67   0.43   99.66   0.45   89.82   5.67   90.17   5.42   90.01   5.45
      Age \> 30 years       100            0.00         100     0.00   100     0.00   99.82   0.23   99.82   0.22   99.81   0.25
      Male                  99.96          0.09         99.96   0.05   99.96   0.05   96.93   2.24   97.07   2.00   97.04   2.08
      Female                100            0.00         100     0.00   100     0.00   99.84   0.18   99.84   0.20   99.83   0.20
  **Endemic region**                                                                                                         
      No                    99.93          0.10         99.94   0.08   99.94   0.08   97.11   1.70   97.19   1.65   97.20   1.50
      Yes                   99.99          0.03         99.99   0.02   99.99   0.02   98.67   1.16   98.72   1.04   98.67   1.14
  **Contact with vector**                                                                                                    
      No                    99.96          0.09         99.96   0.06   99.96   0.06   96.86   2.54   96.95   2.32   96.88   2.43
      Yes                   100            0.00         100     0.00   100     0.00   99.82   0.19   99.83   0.18   99.82   0.19
  **Family history**                                                                                                         
      No                    99.90          0.15         99.91   0.12   99.90   0.12   93.80   3.55   94.00   3.44   93.91   3.40
      Yes                   100            0.01         100     0.00   100     0.00   99.77   0.33   99.78   0.27   99.77   0.33

SD: Standard Deviation

Discussion
==========

In the present study, the general sensitivity rates were 97.76%, 97.70% and 97.64% and the specificity was 97.25%, 98.48% and 98.52% for the ELISA, IHA and IIF tests, respectively. These results show performances similar to those found by Langui Junior et al.^([@R19])^ but the sensitivity of IHA testing was higher in the present study. Studies on screening tests for Chagas disease reported sensitivity rates for the ELISA kit of bioMérieux ranging from 98.38% to 98.5% and specificity rates from 94.30% to 99.93%.^([@R20],[@R21])^ Sensitivity rates ranging from 52.75% to 96.5% and specificity from 87% to 100%^(22-24)^ have been described for IIF. Sensitivity rates from 98.5% to 100% and specificity between 99.69% and 100% have been reported for IHA.^([@R19],[@R20])^Regarding the Bio-Manguinhos-FIOCRUZ kits, Gadelha et al.^([@R22])^found 100% sensitivity and specificity for the c-ELISA kit and sensitivity of 98.2% for the rec-ELISA kit.

Hence, it is essential to continually assess the performance of commercial tests that are still not totally efficacious. Failures in Chagas disease screening, may occur due to cross reactions with other parasites, in particular those of the trypanosomatid genus such as Leishmania which may have many genetic similarities with *T. cruzi*antigens and the same epitopes to bind to antibodiespresent in the sera of infected patients^([@R20],[@R25])^.

The publication of government directives numbers 153 and 57 by ANVISA^([@R26],[@R27])^, made a single technique for the serological screening of blood donors for Chagas disease mandatory and that the blood bank must participate in external quality control programs. Thus it is important to seek screening methods by investigating specific *T. cruzi* antigens which minimize or exclude cross reactions.

Cross reactions in blood banks may be a cause of persistentserological ineligibility due to Chagas disease; this may correspondto up to 80% of inconclusive or false-positive serological results.^([@R08],[@R11],[@R20],2[@R08],[@R29])^ Many studies report that inconclusive samples repeatedlyshowed negative results on using other tests.^([@R11],[@R26])^

As, in this study, the estimated prevalence of Chagas disease was 13.30% in the stratum of donors with inconclusive serology at screening, 86.70% of donors probably do not have Chagas infection. This prevalence rate is well below the rate reported by Furuchó et al.^([@R10])^ who observed that 20.5% of donors in the inconclusive serology group were positive for Chagas disease. In addition, on considering epidemiological variables in this stratum, the absence of Chagas\' infection can be affirmed with a probability of 100% when two tests give negative results in all pairs of serological tests.

Studies in epidemiology and statistics show that an associationof two tests increases the quality of diagnosis, thereby reducing thenumber of false results. The simplest way of forming a set of testsis by using in series or in parallel design^([@R30])^ as used in this study.

Although there is no individual screening test for Chagas disease that has a sensitivity of 100%, sensitivity levels of 99.96% were found for several sets of tests in the parallel analysis. Additionally all pairs of tests (excluding HEMO) had specificities in series testing greater than 99.93% and the set formed by the ELISA, IIF and IHA tests had specificities of 100%, suggesting that this is the best alternative to confirm procedures.

Studies report that the combination of epidemiological data with results of high performance testing allows a more accurate view of the serologic status of donors^([@R10],[@R11])^. To confirm these data, we find estimates for the sensitivity and specificity close to 100% for certain epidemiological covariates suggesting that it is important to consider the inclusion of covariates in the structure of the model to evaluate the performance of the diagnostic tests.

In conclusion, commercial diagnostic tests (ELISA, IIF, HAI, c-ELISA, rec-ELISA) used to screen for Chagas disease, when used in pairs in serial testing schemes, proved to be an interesting alternative to confirm the procedure. In addition, epidemiological variables may contribute to improve the results of these tests and to clarify the true meaning of inconclusive serology screening. In search of a gold standard procedure and more reliable estimates, further studies are necessary with larger samples, clinical variables and further assume dependence between tests in statistical modeling.
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